Rate Video

ASCO 2020 | Axitinib plus pembrolizumab in advanced RCC

Michael Atkins • 26 May 2020

Genitourinary Cancer Kidney Cancer Axitinib Pembrolizumab

Immuno-Oncology

Michael Atkins, MD, of Georgetown University, Washington, DC, reports long-term efficacy and safety from a phase Ib study investigating the combination of axitinib and pembrolizumab in advanced renal cell carcinoma patients. This video was recorded via an online conference call with the Video Journal of Oncology (VJOncology).

The agents at the forefront of kidney cancer treatment

Michael Atkins • 8 Feb 2018

Should sunitinib still be used in the treatment of metstatic kidney cancer?

Michael Atkins • 8 Sep 2017

First-line therapy options for RCC: lessons from CheckMate 214 and KEYNOTE-427

Looking to the future of RCC treatment

Related Videos

Novel biomarkers for outcomes identified in BCG-treated T1HG bladder cancer

Christiaan De Jong • 21 Jul 2021

Improving anti-PD-1/PD-L1 therapy for localized bladder cancer

Christiaan De Jong • 21 Jul 2021

Benefits of T1 substaging for NMIBC

Christiaan De Jong • 21 Jul 2021

Updates on the systemic treatment of metastatic HSPC

Noel Clarke • 16 Jul 2021